Joseph Olobo
Overview
Explore the profile of Joseph Olobo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chu W, Verrest L, Younis B, Musa A, Mbui J, Mohammed R, et al.
J Infect Dis
. 2024 Aug;
230(6):e1375-e1384.
PMID: 39166299
Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to disease-specific variations in absorption, distribution, and...
2.
Verrest L, Monnerat S, Musa A, Mbui J, Khalil E, Olobo J, et al.
PLoS Negl Trop Dis
. 2024 Apr;
18(4):e0012078.
PMID: 38640118
Background: With the current treatment options for visceral leishmaniasis (VL), recrudescence of the parasite is seen in a proportion of patients. Understanding parasite dynamics is crucial to improving treatment efficacy...
3.
Verrest L, Roseboom I, Wasunna M, Mbui J, Njenga S, Musa A, et al.
J Antimicrob Chemother
. 2023 Sep;
78(11):2702-2714.
PMID: 37726401
Objectives: To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated. As the majority of patients affected by...
4.
Musa A, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, et al.
Clin Infect Dis
. 2022 Sep;
76(3):e1177-e1185.
PMID: 36164254
Background: This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa. Methods: An...
5.
Verrest L, Kip A, Musa A, Schoone G, Schallig H, Mbui J, et al.
Clin Infect Dis
. 2021 Feb;
73(5):775-782.
PMID: 33580234
Background: To expedite the development of new oral treatment regimens for visceral leishmaniasis (VL), there is a need for early markers to evaluate treatment response and predict long-term outcomes. Methods:...
6.
Agwang C, Erume J, Okech B, Olobo J, Egwang T
Malar J
. 2020 Oct;
19(1):361.
PMID: 33032613
Background: The development of malaria vaccines is constrained by genetic polymorphisms exhibited by Plasmodium falciparum antigens. The project the age-dependent distribution of alleles or haplotypes of three P. falciparum malaria...
7.
Palic S, Kip A, Beijnen J, Mbui J, Musa A, Solomos A, et al.
J Antimicrob Chemother
. 2020 Aug;
75(11):3260-3268.
PMID: 32780098
Background: Conventional miltefosine dosing (2.5 mg/kg/day) for treatment of visceral leishmaniasis (VL) is less effective in children than in adults. A higher allometric dose (median 3.2 mg/kg/day) was therefore investigated...
8.
Okurut S, Boulware D, Olobo J, Meya D
Mycoses
. 2020 May;
63(8):840-853.
PMID: 32472727
Cryptococcal meningitis remains one of the leading causes of death among HIV-infected adults in the fourth decade of HIV era in sub-Saharan Africa, contributing to 10%-20% of global HIV-related deaths....
9.
Okurut S, Meya D, Bwanga F, Olobo J, Eller M, Cham-Jallow F, et al.
Infect Immun
. 2019 Dec;
88(3).
PMID: 31871098
Activated B cells modulate infection by differentiating into pathogen-specific antibody-producing effector plasmablasts/plasma cells, memory cells, and immune regulatory B cells. In this context, the B cell phenotypes that infiltrate the...
10.
Mbui J, Olobo J, Omollo R, Solomos A, Kip A, Kirigi G, et al.
Clin Infect Dis
. 2018 Sep;
68(9):1530-1538.
PMID: 30188978
Background: Convenient, safe, and effective treatments for visceral leishmaniasis in Eastern African children are lacking. Miltefosine, the only oral treatment, failed to achieve adequate efficacy, particularly in children, in whom...